Travasol 3.5% Sulfite Free W/ Electrolytes In Plastic Container From Baxter Hlthcare With amino Acids; Magnesium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate; Sodium Chloride 3.5%;51mg/100ml;131mg/100ml;218mg/100ml;35mg/100ml

Ingredients: "amino Acids; Magnesium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate; Sodium Chloride"
Dosage Form and Administration: Injectable; Injection
Drug Trade Name: Travasol 3.5% Sulfite Free W/ Electrolytes In Plastic Container
Firm: Baxter Hlthcare
Strength: 3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML
New Drug Application Type: N
Drug Application Number:20177
Product Number: 1
Approval Date: 10/23/1995
Reference Listed Drug: No
Type: RX
Applicant Full Name: Baxter Healthcare Corp

Serving Size

Start with small servings and let the child ask for more if he or she is still hungry. Children need adults to provide them with healthy meals and snacks, but a child should be allowed to choose how much food he or she will eat.
Be aware that some companies market some high fat or high sugar foods and beverages specifically to kids. Usually these products have cartoon characters, offer free toys and come in bright packages. Talk with kids about the importance of fruits, vegetables, whole grains and other healthy foods, even if TV and stores do not advertise these foods.

Substance Abuse and Mental Disorders

It is important to adequately assess mental disorders and to address these diseases as part of effective drug abuse treatment. Specialists can address many types of mental health problems in standard drug abuse treatment programs. However, individuals with serious mental disorders may require an integrated treatment approach designed for treating patients with co-occurring mental health problems and substance use disorders. Although not readily available, specialized therapeutic community Mentally Ill Chemical Abuser programs (MICA) attend to patients with co-occurring mental and addictive problems.
Science has progressed by developing effective medications for treating mental disorders, including a number of antidepressants, anti anxiety agents, mood stabilizers and antipsychotics. These medications may be critical for treatment success in offenders who have co-occurring mental disorders such as depression, anxiety disorders, bipolar disorder or schizophrenia. Cognitive behavioral therapy can be effective for treating some mental health problems, particularly when combined with medications. Contingency management can improve adherence to medications and intensive case management is useful for linking severely mentally ill individuals with drug abuse treatment, mental health care and community services.

Drug Abuse Treatment to Offenders Return on Investment (ROI)

In 2002, the estimated cost to society of drug abuse was $180.9 billion (Office of National Drug Control Policy [ONDCP], 2004), $107.8 billion related to crime related to drugs, including criminal justice system costs and costs borne by victims of crime. The cost of treating drug abuse including research, training and prevention efforts is about $15.8 billion, a fraction of these overall societal costs (ONDCP, 2004).
Drug abuse treatment is cost effective in reducing drug use and bringing about associated healthcare, crime and incarceration cost savings. Positive net economic benefits are consistently found for drug abuse treatment across various settings and populations. The largest economic benefit of treatment is in avoided costs of crime, incarceration and victimization costs, with greater economic benefits resulting from treating offenders with co-occurring mental health problems and substance use disorders. Residential prison treatment is more cost effective if offenders attend treatment after release, according to research (Martin, Butzin, Saum and Inciardi, 1999). Drug courts also convey positive economic benefits, including allowing participants to earn wages and avoid incarceration and future crime costs.
Incarcerated women have high rates of substance abuse, mental disorders and other health problems.